 CAMBRIDGE, Mass.--BUSINESS WIRE--Seres Therapeutics, Inc., Nasdaq: MCRB, a leading microbiome therapeutics company, today reported fourth quarter and full year 2020 financial results and provided business updates. Seres continues to make progress executing against our top corporate priorities. We are enrolling our open label study to support a Biologics License Application BLA for SER-109, a potential first-ever FDA approved microbiome therapeutic. We have also advanced our clinical pipe 